Feed TNXP
TN

Tonix Pharmaceuticals Holding Corp.

TNXP · NASDAQ

$11.73 -0.42% (-$0.05)
1M -6.24%
Market Cap $189.2M
P/E Ratio -
Div. Yield -
ROE 68.99%

Bulios Fair Price

$14.64

24.8% upside

Trenutna cena

$11.73

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica TNXP trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
60 /100
Fair
P/B 0.85x
P/S 6.50x
EV/EBITDA N/A
Growth
55 /100
Stable
Book val. growth 5.77%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Net margin 548.64%
Op. margin 568.43%
FCF margin 549.41%
Quality
2 /100
Poor
ROE 68.99%
ROA 62.84%
Asset turnover 0.11x
Debt
100 /100
Low
Current ratio 6.61x
Debt/Equity 0.01x
Net debt/EBITDA N/A
Stability
6 /100
Unstable
EPS volatility 449.84%
Profitable years 0
Beta 1.75x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o TNXP
Online

O podjetju

Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company focused on developing drugs for the treatment of psychiatric and neurological disorders. Their main product candidates include medicines for the treatment of post-traumatic stress disorder (PTSD), fibromyalgia, and migraines. Tonix Pharmaceuticals focuses on utilizing advanced biotechnological methods and clinical trials to discover new treatment options for patients suffering from these conditions. The company is active in research and development and conducts clinical trials to assess the efficacy and safety of its medicinal products. Tonix Pharmaceuticals Holding Corp. (TNXP) shares could be suitable for investors looking for opportunities in the biopharmaceutical sector with a focus on the treatment of psychiatric and neurological disorders.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Seth Lederman

Employees

142

Headquarters

Berkeley Heights

Prihajajoči dogodki

09 NOV.

Earnings

Upcoming earnings report

56d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.